Holen Sie sich die Stockscreener-App
2.37
3.27%
-0.08
Handel nachbörslich:
2.36
-0.01
-0.42%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt BCLI?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$2.45
Offen:
$2.27
24-Stunden-Volumen:
154.30K
Relative Volume:
1.39
Marktkapitalisierung:
$13.52M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-16.63M
KGV:
-4.0169
EPS:
-0.59
Netto-Cashflow:
$-21.84M
1W Leistung:
+14.49%
1M Leistung:
+36.21%
6M Leistung:
-53.32%
1J Leistung:
-42.12%
1-Tages-Spanne:
$2.13
$2.4507
1-Wochen-Bereich:
$2.09
$2.50
52-Wochen-Spanne:
$1.05
$11.89
Brainstorm Cell Therapeutics Inc Stock (BCLI) Company Profile
Firmenname
Brainstorm Cell Therapeutics Inc
Sektor
Branche
Telefon
201-488-0460
Adresse
1325 AVENUE OF AMERICAS, NEW YORK, NY
Vergleichen Sie BCLI mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
BCLI
Brainstorm Cell Therapeutics Inc
|
2.37 | 13.52M | 0 | -16.63M | -21.84M | -0.43 |
|
VRTX
Vertex Pharmaceuticals Inc
|
399.35 | 102.84B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
702.59 | 77.21B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
619.96 | 37.07B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
236.01 | 30.44B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
112.58 | 26.99B | 3.30B | -501.07M | 1.03B | -2.1146 |
Brainstorm Cell Therapeutics Inc Stock (BCLI) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2021-02-04 | Hochstufung | Maxim Group | Hold → Buy |
| 2020-11-17 | Herabstufung | Maxim Group | Buy → Hold |
| 2016-12-19 | Bestätigt | Maxim Group | Buy |
| 2015-12-22 | Bestätigt | Maxim Group | Buy |
Brainstorm Cell Therapeutics Inc Aktie (BCLI) Neueste Nachrichten
BrainStorm Cell Therapeutics Announces Key Milestones and Strategic Plans for ALS Therapy NurOwn® - Tandav Media
BrainStorm Issues 2024 Letter to Shareholders - PR Newswire
BrainStorm Cell Therapeutics to Host Investor Call and Provide a Corporate Update - The Eastern Progress Online
BrainStorm Cell Therapeutics Announces Presentations on NurOwn® at 2024 Annual NEALS Meeting - The Eastern Progress Online
BrainStorm Cell Therapeutics to Host KOL Webinar on Current Developments in the Treatment of Amyotrophic Lateral Sclerosis (ALS) on December 11, 2024 - The Eastern Progress Online
Amyotrophic Lateral Sclerosis (ALS) Market: Segmentation - openPR
BrainStorm Cell Therapeutics Announces Major ALS Treatment Webinar with Leading Expert - StockTitan
BrainStorm Cell Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement - Kilgore News Herald
Autologous Cell Therapy Market Expected to Grow at Rapid Rates - openPR
BrainStorm secures patent for exosome technology By Investing.com - Investing.com Nigeria
BrainStorm Strengthens Exosome Patent Portfolio: Receives Notice of Allowance for U.S. Patent Covering Its Platform Technology - Lelezard
BrainStorm secures patent for exosome technology - Investing.com
Breakthrough Patent Propels BrainStorm’s Next-Gen Therapies - Smartphone Magazine
BrainStorm Cell Therapeutics and Pluri Partner to Support NurOwn® Phase 3b Trial Manufacturing - Marketscreener.com
Gene and Cell Therapies Targeting CNS Disorders Treatment Market 2034: Clinical Trials, EMA, PDMA, FDA Approvals, Medication, Revenue, Statistics, Therapies, Prevalence, Companies by DelveInsight - The Globe and Mail
Gene and Cell Therapies Targeting CNS Disorders Treatment - openPR
BrainStorm Cell Therapeutics Regains Compliance with Nasdaq Mini - GuruFocus.com
Brainstorm Cell Therapeutics Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Stem Cell Therapy Market to Reach $19.1 Billion by 2031 | Advanced - openPR
Brainstorm Cell Therapeutics Inc. (BCLI) Quarterly 10-Q Report - Quartzy
ARMISTICE CAPITAL, LLC Expands Stake in Brainstorm Cell Therapeu - GuruFocus.com
BrainStorm Cell Therapeutics Announces Third Quarter 2024 Financial Results and Provides Corporate Update - The Malaysian Reserve
BrainStorm Cell Reports $2.7M Loss, Plans Phase 3b ALS Trial Despite Low Cash | BCLI Stock News - StockTitan
75+ Key Companies Charting New Frontiers in Multiple Sclerosis Therapeutic Space | DelveInsight - The Malaysian Reserve
Amyotrophic Lateral Sclerosis Market Opportunities, - openPR
BrainStorm Teams with Pluri for Key NurOwn ALS Trial Manufacturing Partnership - StockTitan
Amyotrophic Lateral Sclerosis Treatment Market to Grow by USD 663.7 Million from 2024-2028, as Rising Incidence Drives Demand with AI Redefining Market LandscapeTechnavio - The Malaysian Reserve
BCLI stock touches 52-week low at $1.45 amid market challenges - Investing.com
BCLI stock touches 52-week low at $1.86 amid market challenges - Investing.com
BrainStorm regains Nasdaq compliance with bid price rule By Investing.com - Investing.com South Africa
BrainStorm regains Nasdaq compliance with bid price rule - Investing.com India
Neuromuscular Disease Therapeutics Market Statistical - openPR
BrainStorm Cell Therapeutics Presented Positive Survival Data from NurOwn® Expanded Access Program at 2024 Annual NEALS Meeting - PR Newswire
Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) Short Interest Update - MarketBeat
Brainstorm Cell Therapeutics (NASDAQ:BCLI) Shares Cross Above 200-Day Moving AverageShould You Sell? - MarketBeat
Amyotrophic Lateral Sclerosis (ALS) Market: Detailed Analysis - openPR
ROSEN, NATIONAL TRIAL LAWYERS, Encourages Brainstorm Cell Therapeutics Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the FirmBCLI - AsiaOne
Stem Cell Therapy Market Projected to Reach $831.9 Million By 2032 - 대구포스트
Short Interest in Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) Declines By 91.1% - MarketBeat
Autologous Stem Cell and Non-Stem Cell Based Therapies Industry Report By Type, Application and Geography - Elektrotransports.lv
Brainstorm Cell Therapeutics (NASDAQ:BCLI) Coverage Initiated at StockNews.com - MarketBeat
BCLIBrainstorm Cell Therapeutics Inc. Latest Stock News & Market Updates - StockTitan
BrainStorm Cell Therapeutics to Provide Corporate Update on Phase 3b NurOwn® Trial at the 2024 Maxim Healthcare Virtual Summit - StockTitan
Gene and Cell Therapies for CNS Disorders Market to Experience - openPR
Finanzdaten der Brainstorm Cell Therapeutics Inc-Aktie (BCLI)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.76%
1.06%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):